• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Med . Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study

tetano

Editor, Senior Moderator
Ann Med


. 2021 Dec;53(1):770-776.
doi: 10.1080/07853890.2021.1931957.
Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study


Li Zhong[SUP] 1 [/SUP], Yuting Wu[SUP] 2 [/SUP], Jinghua Gao[SUP] 3 [/SUP], Jinxia Zhang[SUP] 4 [/SUP], Qifeng Xie[SUP] 5 [/SUP], Huang He[SUP] 6 [/SUP], Jingjing Ji[SUP] 3 [/SUP], Zheying Liu[SUP] 3 [/SUP], Conglin Wang[SUP] 3 [/SUP], Zhifeng Liu[SUP] 3 7 [/SUP]



Affiliations

Abstract

Objectives: Hypertension is thought to be a contributor to mortality in coronavirus disease 2019 patients; however, limited clinical data on the outcomes of COVID-19 in patients with hypertension are available.Methods: This study was designed to confirm whether hypertension affects the outcomes of COVID-19. Results: A total of 983 patients with COVID-19 (female, 48%; male, 52%) were enrolled. Significantly higher odds of 60-day mortality (p = .017) were observed in the hypertensive group. In the hypertensive group, even after adjustment in multivariate analysis, the subgroup of patients 70 years old and older had higher 28-day mortality and total 60-day mortality rates than the other age subgroups (bothp < .05). A total of 297 (89%) COVID-19 patients with hypertension survived, and 35 (11%) died. In addition, compared with hypertensive patients who survived COVID-19, non-survivors had more pre-existing conditions, including cardiovascular diseases and stroke, higher blood pressure on admission, more severe inflammation, and more liver and kidney damage.Conclusion: Hypertension does not affect the outcome of COVID-19, which is different than the conclusions drawn in other studies. However, the 28-day mortality and total 60-day mortality rates of hypertensive patients (age ≥ 70) with COVID-19 were significantly elevated, and compared with the group of survivors, non-surviving COVID-19 patients with hypertension were older, had more basic diseases and had a more severe clinical condition.

Keywords: COVID-19; age; clinical characteristics; hypertension; mortality.
 
Back
Top Bottom